MedTrace Logo

Immunosupressive Treatment in COVID-19 Patients

NCT04382781 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2020-05-12

No results posted yet for this study

Summary

SAM-COVID is a retrospective cohort study that aims to determine the impact of immunosuppressive drugs and immunoglubulins in the outcome of patients with COVID-19.

Conditions

  • COVID-19 Infection

Interventions

DRUG

NO-Immunosuppressive

Patients not receiving immunosuppressive drugs

DRUG

Immunosuppressive

Patients receiving immunosuppressive drugs (overall, and specific drugs)

DRUG

Immunoglubulins

Patients receiving immunoglubulins

Sponsors & Collaborators

  • Fundación Pública Andaluza para la gestión de la Investigación en Sevilla

    collaborator OTHER

  • Spanish Network for Research in Infectious Diseases

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-31
Primary Completion
2020-05-31
Completion
2020-05-31

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04382781 on ClinicalTrials.gov